Heartburn Research Today is a free monthly online journal that collates and summarizes the latest research about Heartburn, including details on symptoms, causes, prevention, treatment, diet, reflux, drugs.

Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, PO Box 85500, Utrecht, Netherlands, 3508 GA.

Published 11 November 2010 in Cochrane Database Syst Rev, 11: CD002095.
Full-text of this article is available online (may require subscription).

Articles on Heartburn published 9 June 2010:

Heartburn and regurgitation in pregnancy: the effect of fat ingestion.   Dig Dis Sci, 55(6): 1610-4.

BACKGROUND: Reflux symptoms are common in pregnancy, but their association with fat ingestion is unclear. AIM: To investigate an association of dietary fats with heartburn and regurgitation in pregnancy. METHODS: This is a prospective study in which 89 pregnant women (gestational age 34 +/- 4 weeks) attending a low-risk prenatal outpatient clinic were asked to provide information on the frequency they experienced heartburn and regurgitation. Fat ingestion was estimated by means of a 24-h diet ... [Abstract] [Full-text]

Articles on Heartburn published 9 September 2009:

Influence of intra-oesophageal capsaicin instillation on heartburn induction and oesophageal sensitivity in man.   Neurogastroenterol Motil, 21(10): 1032-e82.

Heartburn is the most typical gastro-oesophageal reflux disease (GERD) symptom. The transient receptor potential vanilloid receptor-1 (TRPV(1)) is a candidate mediator of heartburn. Exposure of TRPV(1) to capsaicin is characterized by activation, followed by desensitization. Our aim was to investigate the effect of intra-oesophageal capsaicin instillation on oesophageal symptom perception (activation) and on sensitivity to oesophageal acid perfusion and oesophageal balloon distention ... [Abstract] [Full-text]

Articles on Heartburn published 12 August 2009:

Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease.   Gut, 58(9): 1185-91.

INTRODUCTION: Functional dyspepsia and non-erosive reflux disease (NERD) are prevalent gastrointestinal conditions with accumulating evidence regarding an overlap between the two. Still, patients with NERD represent a very heterogeneous group and limited data on dyspeptic symptoms in various subgroups of NERD are available. AIM: To evaluate the prevalence of dyspeptic symptoms in patients with NERD subclassified by using 24 h impedance-pH monitoring (MII-pH). METHODS: Patients with typical ... [Abstract] [Full-text]

Articles on Heartburn published 31 July 2009:

Association of heartburn and laryngopharyngeal symptoms with endoscopic reflux esophagitis, smoking, and drinking.   Otolaryngol Head Neck Surg, 141(2): 264-71.

OBJECTIVES: This study was conducted to investigate the association of laryngopharyngeal symptoms and heartburn with endoscopic esophagitis, smoking, and drinking. The clinical importance of the Reflux Symptom Index (RSI) in predicting endoscopic esophagitis was also evaluated. STUDY DESIGN: Case series with planned data collection. SUBJECTS AND METHODS: From November 2006 to February 2007, 156 adults received a whole-body physical check-up. They filled out the RSI questionnaire and were ... [Abstract] [Full-text]

Articles on Heartburn published 30 June 2009:

Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.   Gastroenterology, 137(1): 80-7, 87.e1.

BACKGROUND & AIMS: Rebound acid hypersecretion (RAHS) has been demonstrated after 8 weeks of treatment with a proton-pump inhibitor (PPI). If RAHS induces acid-related symptoms, this might lead to PPI dependency and thus have important implications. METHODS: A randomized, double-blind, placebo-controlled trial with 120 healthy volunteers was conducted. Participants were randomized to 12 weeks of placebo or 8 weeks of esomeprazole 40 mg/d followed by 4 weeks with placebo. The ... [Abstract] [Full-text]

Articles on Heartburn published 3 June 2009:

The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis.   Am J Gastroenterol, 104(6): 1541-5; quiz 1540, 1546.

OBJECTIVES: Heartburn and acid reflux are common medical disorders in pregnancy and can result in serious discomfort and complications. Furthermore, some pregnant women also experience more severe gastrointestinal conditions, such as Helicobacter pylori infections, peptic ulcers, and Zollinger-Ellison syndrome. To allow the use of proton pump inhibitors (PPIs) in pregnancy, the fetal safety of this drug class must be established. The aim of this study is to determine the fetal safety of PPIs ... [Abstract] [Full-text]

Articles on Heartburn published 7 May 2009:

Upper gastrointestinal symptoms and associated disorders in morbidly obese patients: a prospective study.   Dig Dis Sci, 54(6): 1243-6.

OBJECTIVE: To prospectively evaluate the frequency of upper gastrointestinal symptoms and associated disorders in morbidly obese patients with endoscopy and histology prior to their gastric bypass surgery in comparison with age- and sex-matched nonobese control subjects. METHODS: All patients who were scheduled to undergo laparoscopic gastric bypass for treatment of morbid obesity (body mass index, BMI > 40 kg/m(2)) during a 1-year period (n = 101) were included in the study. Age- and ... [Abstract] [Full-text]

Articles on Heartburn published 5 May 2009:

Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.   South Med J, 102(5): 486-92.

OBJECTIVE: This subanalysis of CURRENT, an open-label, 6-month, multicenter study, assesses changes in gastrointestinal (GI) tolerability with once-monthly oral ibandronate in women who switched from once-weekly bisphosphonates and had reported GI symptoms with their previous weekly bisphosphonate regimen. METHODS: Postmenopausal women currently taking a weekly bisphosphonate switched to 150 mg monthly ibandronate. At the start of the treatment phase and after 6 months of therapy, all ... [Abstract] [Full-text]

© 2004-2011 Heartburn Research Today. All Rights Reserved.